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The International Genetics & Translational Research in Transplantation Network (iGeneTRAiN)
Background.Genetic association studies of transplantation outcomes have been hampered by small samples and highly com-
plex multifactorial phenotypes, hindering investigations of the genetic architecture of a range of comorbidities which significantly
impact graft and recipient life expectancy. We describe here the rationale and design of the International Genetics & Translational
Research in Transplantation Network. The network comprises 22 studies to date, including 16 494 transplant recipients and
11669 donors, of whom more than 5000 are of non-European ancestry, all of whom have existing genomewide genotype data
sets.Methods.We describe the rich genetic and phenotypic information available in this consortium comprising heart, kidney,
liver, and lung transplant cohorts.Results.We demonstrate significant power in International Genetics & Translational Research
in Transplantation Network to detect main effect association signals across regions such as the MHC region as well as
genomewide for transplant outcomes that span all solid organs, such as graft survival, acute rejection, new onset of diabetes after
transplantation, and for delayed graft function in kidney only. Conclusions. This consortium is designed and statistically
powered to deliver pioneering insights into the genetic architecture of transplant-related outcomes across a range of different
solid-organ transplant studies. The study design allows a spectrum of analyses to be performed including recipient-only analyses,
donor-recipient HLA mismatches with focus on loss-of-function variants and nonsynonymous single nucleotide polymorphisms.
(Transplantation 2015;99: 2401–2412)
Recent advances in genomics, including genomewide as-sociation studies (GWAS), second-generation sequenc-
ing (SGS), and their application within appropriately powered
and carefully phenotyped studies, have yielded meaningful in-
sights into the understanding of the molecular basis of a multi-
tude of common and rare diseases.1-3 The GWAS and SGS
studies have identified genes inactivated by homozygous loss-
of-function (LoF) mutations,4 including both single-nucleotide
variants and large homozygous deletion copy number variants
(hdCNVs) which can span exons or even entire genes.5-7 Such
LoFs have shown clinical importance in the pathophysiology
of graft-versus-host disease in hematopoietic cell transplantation
(Tx) studies.7 Large-scale SGS studies also show gene-coding re-
gions that are unique population-specific sequences,8 and such
population-specific differences may underpin allogenicity in eth-
nically diverse donor-recipient (D-R) transplant pairs indepen-
dent of HLA matching.
Received 30 April 2015. Revision received 11 June 2015.
Accepted 4 July 2015.
This project was funded in part by Fundación Mutua Madrileña, Spain. Part of this
work is also supported by the Dutch PLN Foundation (www.stichtingpln.nl).
Folkert W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research
Centre and by a Dekker scholarship-Junior Staff Member 2014T001—
Netherlands Heart Foundation. Partial funding was also provided by the Deanship
of Scientific Research at King Saud University, Riyadh. We also acknowledge
funding from the following NIH grants: U01 HG006830; U01-DK062494;
UM1AI109565; U01-AI63589 and U19-AI070119.
The authors declare no funding or conflicts of interest.
A.K.I., A.S., and F.W.A. contributed equally to this article.
B.J.K., A.K.I.,W.O., P.A.J., A.S., and F.W.A. conceived the study. Y.R.L., J.vS., Y.L.,
M.V.H., S.S.V., M.L., N.N., H.G., H.C., K.J.K., B.A., H.C., W.G., T.G., D.S.M., T.W.,
D.G.M.A., M.B.L., H.H., K.B., M.D.R., P.A.J., F.W.A., A.K.I., A.S., and B.J.K. were
involved in acquisition of data, analysis, and/or interpretation of data. B.J.K., P.A.
J., M.V.H., J.v.S., W.S.O., K.A.B., S.J.L.B., A.K.I., M.B.L., A.S., and F.W.A. were
involved in drafting the manuscript and critical revisions. E.M., V.T., L.S., T.L., J.G.,
B.A., H.C., A.H., J.v.H., A.P., R.U., E.C., A.A.A., F.A.A., A.M.A., B.M., Y.R.L., J.v.
S., Y.L., M.V.H., S.S.V., M.L., N.N., H.G., H.C., K.J.K., C.W., M.M., K.M.O., C.W.,
T.W., M.K., S.B., M.B.L., W.S.O., P.G.P., D.G.M.A., P.A.J., F.W.A., A.K.I., A.S.,
B.J.K., and all other coauthors were involved in collection of phenotype data
and/or critical contributions to the framework of the consortium. All coauthors
read and approved the final article, and are accountable for all aspects and
integrity of the work.
Correspondence: Brendan J. Keating, D.Phil., Division of Transplantation, 2 Dulles, Hospital
of the University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104
(bkeating@mail.med.upenn.edu); Ajay Israni, MD, Department of Nephrology, Hennepin
Medical Center, 730 S 8th St, Minnesota, MN 55415 (isran001@umn.edu); Abraham
Shaked, MD, PhD, Division of Transplantation, 2 Dulles, Hospital of the University of
Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104 (Abraham.Shaked@uphs.
upenn.edu); Folkert Asselbergs, MD, PhD, Department of Cardiology, Division Heart &
Lungs, University Medical Center Utrecht, Room E03.511, P.O. Box 85500, 3508GA
Utrecht, the Netherlands (F.W.Asselbergs@umcutrecht.nl).
Supplemental digital content (SDC) is available for this article. Direct URL citations
appear in the printed text, and links to the digital files are provided in the HTML
text of this article on the journal's Web site (www.transplantjournal.com).
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open-
access article distributed under the terms of the Creative Commons Attribution-
Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible
to download and share the work provided it is properly cited. The work cannot be
changed in any way or used commercially.
ISSN: 0041-1337/15/9911-2401
DOI: 10.1097/TP.0000000000000913
OriginalClinicalScienceçGeneral
Transplantation ■ November 2015 ■ Volume 99 ■ Number 11 www.transplantjournal.com 2401
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Association of transplant outcomes and polymorphisms in
HLA and natural killer (NK) cell immunoglobulin-like recep-
tor (KIR) regions are well established9-11 HLA Class Imole-
cules are recognized to act as ligands for KIR on NK cells.
The KIR plays essential roles in regulating the ability of NK
cells to sense and respond to HLA Class I surface
expression, which have been shown to be important in
allorecognition.12 Many unique KIR haplotypes have been
identified, and these are unevenly distributed across human
populations in a manner similar to HLA.13 In 10 years of
follow-up, 18%of deceased donor kidney graft failureswere at-
tributable to HLA factors, whereas more than double that pro-
portion (38% of failures) were due to immunological reactions
against non-HLA factors.14 Incorporating our knowledge of
known clinical predictors of graft survival and complications,
genetic studies could improve our understanding of immuno-
logical reactions to both HLA and non-HLA factors.
Next to the identification of immunological factors, geno-
mic studies focusing on a priori gene regions of pharmacolog-
ical relevance have led to the discovery of polymorphisms
underpinning variance in trough blood concentrations of
immunosuppressant therapies (ISTs)15-17 Personalizing drug
treatment for patients to achieve optimal dosing using predic-
tive panels of pharmacogenomicmarkers has begun to be real-
ized within general medicine,18 and such pharmacogenomic
approaches will undoubtedly promote better outcomes in the
post-transplant drug treatment settings by allowing more pre-
cise targeting for immunologic tolerance and reduction of IST
toxicities and complications.
Although acute rejection (AR), graft survival, and the
other posttransplant outcomes have known genetic under-
pinnings, they are also heavily influenced by nongenetic fac-
tors, including ischemia reperfusion injury, recipient waiting
list time, noncompliance, and donor organ quality which
limit the effect any given genetic variant will have on the iden-
tified phenotype. However, such covariates can be integrated
into analyses and risk models. The transplant setting could
greatly benefit from GWAS and SGS studies for a variety of
reasons including discovery of additional HLA and non-
HLAD-R genomic incompatibilities thatmay underpin rejec-
tion and insights gained into primary disease recurrence and
important comorbidities, such as new onset of diabetes after
transplant (NODAT). This is especially important as the ma-
jority of recipients require exposure to potent ISTs for the
remainder of their lives and as such the identification of
gene-drug interactions and development of strategies for
avoiding harmful interactions in susceptible individuals is
significant. Because transplant phenotypes, such as AR states,
are highly complex traits with multifactorial components at
the donor and recipient physiological and genomic level, as
well as environmental and treatment settings, scientific ad-
vances are challenging. Such phenotyping issues further
compound GWAS power constraints for discovery (reviewed
by Stegall et al19). To date, there have been 2 transplant-
related GWAS published in well-phenotyped cohorts,20,21
which showed compelling findings despite modest patient
numbers.
The International Genomics & Translational Research in
Transplantation Network (iGeneTRAiN) was established to
bring together genomic data and well-curated heart, kidney,
liver, and lung transplant phenotype data sets. Genome-wide
genotype data are available from more than 28000
individuals to date, of whom more than 5000 are of non-
European ancestry and afford ample statistical power for
meta-analyses of a number of key transplant phenotypes.
The initial aims of iGeneTRAiN include the discovery and val-
idation of genomic underpinnings of rejection and Tx compli-
cations, with the ultimate goal to translate this information
into clinical applications, such as patient-specific IST selection
and dosing, better genomic compatibility matching of D-R
pairs and improved rejection monitoring. In this paper we
present: the study characteristics of the iGeneTRAiN cohorts
with existing genotype data; the strategies for harmonization
of proposed GWAS using imputation; prioritization and har-
monization of the initial phenotypes of interest and analytical
strategies for association studies and functional annotation of
findings from these studies. iGeneTRAiN provides a required
standard framework for the curation of phenotypes, imputa-
tion of genotypes and analytical strategies across studies that
will yield increased statistical power through aggregation of
large-scale data sets compared to traditional smaller single
independent studies.
METHODS
iGeneTRAiN Studies
The respective iGeneTRAiN study designs and character-
istics for subjects recruited with existing GWAS data are
outlined in Table 1. In total, there are over 16 494 recipients
with 11669 donors across the 4 solid organs. The existing
GWAS include participants with a wide geographic represen-
tation across the United States, The Netherlands, United
Kingdom, Ireland, Spain, andAustralia. Themajority of trans-
plant recipients in the studies are adults with the exception of
2 cohorts, which comprise approximately 1060 pediatric
subjects. The study designs are primarily single or multisite
prospective cohorts, and although a small number are retro-
spective in recruitment approach, most are continuing to ac-
crue longitudinal transplant phenotypes and outcome events.
Approximately 18900 samples were subjected to GWAS using
a transplant-specific genomewide genotyping array (described
below) and approximately 8600 additional samples genotyped
using conventional GWAS arrays. The iGeneTRAiN studies
range in size from less than 100 D-R pairs to several thousands
of recipients. All kidney studies and 2 liver studies have varied
proportions of living donor versus deceased donors. Of the
16 494 recipients, approximately 81.3%, 12.1%, 1.7%, and
4% are of are of European, African, Asian, and Hispanic an-
cestry, respectively, with the remainder classified as “other,”
and approximately 62% of D-R pairs have conventional 2-
or 4-digit HLA typing available. Table S1 (SDC, http://
links.lww.com/TP/B191) outlines information regarding spe-
cific clinical HLA typing performed, pretransplant anti-HLA
immunization status, including peak panel-reactive antibody
(PRA), and posttransplant recording of de novo anti-HLA an-
tibodies across each of the 22 studies.
Phenotypes and Disease Endpoints
Collation and Harmonization of Phenotypes
Four primary phenotypes have been selected for ease of
harmonization and of greatest clinical impact: (1) graft sur-
vival, (2) AR, (3) NODAT, and (4) delayed graft function
(DGF). Length of allograft survival after Tx is arguably the
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most important clinical outcome, and although many com-
plex factors underpin it, graft survival is a hard outcome
which can be unequivocally adjudicated. Acute rejection is
an important cause of morbidity and mortality, irrespective
of organ, in transplant recipients and has important sub-
types: antibody-mediated, cellular, and mixed rejection. Pa-
tients who develop AR are at higher risk for chronic graft
dysfunction development, which can progress to graft loss.34
Short term (1 year) allograft and patient survival rates are ex-
cellent in organs, such as kidney, at 90% to 95%, but long-
term outcomes are poor with approximately 50% of kidney
allografts failing after 6 to 11 years.35 Kidney transplant pa-
tients with chronic graft dysfunction can typically return to
dialysis; however, recipients of other organs may die from
chronic allograft dysfunction. New onset of diabetes after
transplant is a serious complication impacting recipient mor-
bidity with a cumulative incidence of 15% to 30% at 1 year
after kidney Tx.36 Cohort studies of solid organ transplant
recipients indicate that patients who develop NODAT are at
increased risk of fatal and nonfatal CVD events as well as
other comorbidities, including infection, graft rejection, and
reduced survival.37 Certain ISTs, such as tacrolimus, are con-
sidered to be toxic to islet cells, causing NODAT. Delayed
graft function is a commonly observed posttransplant ad-
verse event that impacts deceased donor graft survival.38
More complex phenotypes related to pharmacogenomics,
disease recurrence, and skin cancer are actively being investi-
gated for the second wave of meta-analyses.
The primary phenotypes described above were collected,
arbitrated, and harmonized as follows:
(a) Graft survival is defined as the number of days of function-
ing organ (inclusive of retransplant metrics and return to dial-
ysis for kidney recipients). We have also measured patient
survival which we defined as the number of living days after
Tx. Concordance was assessed in each site using internal data
coordinating centers (DCC) and/or respective hospital re-
cords, and national registry databases.
(b) Acute rejection is defined as biopsy proven rejection (de-
fined by Banff or other international criteria) that was clini-
cally treated with standard IST/steroid regimes. Borderline
rejection episodes, mixed, and cellular rejection were system-
atically recorded in most sites.
(c) NODAT is defined as a new diagnosis of diabetes that oc-
curred after Tx and required continued antidiabetic pharma-
cotherapy. Where possible, NODAT was strictly defined as a
new requirement for oral hypoglycemic agents or insulin for
the management of hyperglycemia at a 6-month, 12-month
or 2-year period after Tx.
(d) DGF, limited in the first iteration of the iGeneTRAiN pro-
gram to the kidney cohorts, is defined as the requirement for di-
alysis within the first 7 days after Tx. The DGF analysis includes
the genomics of chronic renal allograft rejection, transplant-
LINES Genetics, Vanderbilt, UPenn and The Long-Term Deteri-
oration of Kidney Allograft Function Study Genomics/GEN-03
studies, with incidence rates of 20%, 33%, 9%, 16%, and
9%, respectively.
Analytical Approaches
Association Studies
Our primary analyses will test for genotype differences be-
tween recipients and D-R pairs, who encounter the clinical
outcomes described above. For graft loss/patient survival,
NODAT, and AR, survival analyses will be performed using
Cox regression with genotype as the primary exposure,
whereas for AR (anytime), NODAT, and DGF, analyses
will be performed using logistic regression with genotype as
the primary exposure. All models will be adjusted for
phenotype-specific covariates (see below). For D-R paired
analyses, we will analyze: (1) quantified total number of
HLA allele mismatches across the genome; (2) the number and
distributions of polymorphisms (and amino acid) discrepancies
between D-R pairs; (3) nonsynonymous single-nucleotide
polymorphisms; and (4) LoFs, grouped by functional impli-
cation. Covariates that will be considered in the regression
models include recipient age, sex, body mass index, year of
transplantation, diabetes status, primary diagnosis, previous
transplant, peak PRA, preemptive Tx,HLA-A, -B, -DRmis-
matches; donor age, sex, graft status (deceased/living), cause
of death (for deceased donors), principal components of an-
cestry computed from available genotype data (to identify
and correct for population substructure), transplant center,
cytomegalovirus status, and ischemic time. Where collected
for clinical use, PRA measurements will be analyzed for be-
tween cohort and between center variation, with the prospec-
tive collection made using the Luminex technology where
possible. For all D-R pairs, we will compute an HLA-based
mismatch score to reflect the genetic compatibility between
donor and recipient, which we will test in all models for each
D-R pair for association with clinical outcomes.
For the AR analysis, we will examine cause-specific rejec-
tion as a categorical variable (antibody-mediated, cellular,
and mixed rejection) by organ type and as a collapsed (any
rejection) variable, stratified by organ, as well as combined
across all organs. We will also perform sensitivity analyses in
which borderline rejection, positive protocol, or surveillance
biopsies positive for AR and “for-cause” biopsies assessed as
nonrejecting are analyzed separately as well as collectively. A
separate sensitivity analysis will also be conducted with
organ-specific AR assessed alone and subtypes of rejection to
determine if any GWAS signals are evident in the combined
“all AR types” data sets and/or subsets analyses.
HLA Imputation and Interaction Analyses
The HLA imputation is carried out using SNP2HLA
which has been described in detail elsewhere.39 Two-
way statistical gene-gene interactions are defined as a
departure from additively on a log odds scale, which
can be statistically tested for genetic markers a and b
using a logistic regression model of the following form:
logit PðY ¼ 1 Δ; Cj Þð Þ ¼ β0 þ∑ki¼1βCi Ci þ βδa δa þ βδb δb þ βδaδb δa δb
where Y represents a binary phenotype, for example, indica-
tor of transplant rejection; δi is a measure of differential ge-
netic variation between donor and recipient for a specific
genetic marker, for example, the difference in the number
of risk alleles for an allele (or amino acid derived from
SNP2HLA [see below]), and Ci is a clinical covariate mea-
sured on the dyad. Given this model, the null hypothesis of
no interaction between δa and δb can be specified as H0 :
βδaδb ¼ 0. To improve the statistical power to detect such in-
teractions, the proposed method uses a screening-testing ap-
proach inspired by recent gene x environment detection
methods.40-42
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Functional Variant Analyses
To identify variants thatmay be potentially pathogenic, in-
cluding LoF variants, we will use the Loss of Function Tran-
script Effect Estimator (http://github.com/konradjk/loftee)
which can be used with existing variant effect predictor soft-
ware packages.43We will compare the allele frequencies with
over 63000 exomes from the Exome Aggregation Consor-
tium to assess rarity of these events, and potential conse-
quences on coding sequence expression. Additionally, we
will intersect these variants with functional markers from
the ENCODE project44 to assess whether the variants may
have an effect at a regulatory level. Finally, we will leverage
RNA-Seq data from the Genotype-Tissue Expression pro-
ject45 to observe whether the variants have an effect on tran-
scription in various tissues.
Organization and Governance
Informed andwritten consent was obtained independently
for each iGeneTRAiN study participant, with appropriate
oversight and approvals from respective local institutional
review boards/Research Ethics Committees to use either
summary-level or anonymized individual-level data.
The iGeneTRAiN network selected 4 solid-organs for
collation and harmonization of the appropriate covariates,
intermediate phenotypes, and outcomes to an acceptable
standardization quality amongst the working groups. Each
iGeneTRAiN Phenotyping Committee has been charged
with: (a) fully harmonizing the genotype and phenotype data
sets across all studies; (b) validating the integrity of these data
sets; and (c) annual updates for event accruals and pheno-
typic measurements (where available). A hematopoietic cell
Tx working group is planned for the near future.
Four overarching working groups, whose interests
span all solid organ phenotypes, were also formed:
(a) HLAworking group, (b) genomic and other omics groups
(including genomic analysis of SGS/GWAS/other genetic
data), (c) pharmacogenomics, and (d) a steering committee
comprised of representatives from the working groups (see
www.igenetrain.org for committees). The iGeneTRAiN se-
nior investigators, comprising the steering group, have pro-
posed and will carry key projects forward and assess
opportunities to include additional collaborators, especially
for non-European populations, and to leverage existing phe-
notype and DNA sets (from organ procurement organiza-
tions and/or hospital HLA laboratories). Although each
site/study has their own DCC(s), for the purposes of the
broader iGeneTRAiNmeta-analyses, summary level (or indi-
vidual level where possible) analyses of GWAS/SGS data for
phenotypes of interest are deposited in 3 independent sites,
which also coordinate imputation of GWAS data across
sites in collaboration with the Center for Systems Genomics,
Pennsylvania StateUniversity, PA. The overarching iGeneTRAiN
DCC is responsible for protocol development and generating
statistical designs, including data collection and cleaning and
data analysis strategy (in coordinationwith the iGeneTRAiN
Statistical Group). The DCC provides data update collection
and data management forms; coordinates statistical analysis
across the groups outlined in Table 1; collaborates in manu-
script preparation; and provides overall coordination and
quality assurance, including coordination of the activities
of the data monitoring, the Statistical Group and Phenotyp-
ing Committees, and other iGeneTRAiN solid-organ and
working groups. In addition, DCC provides continued sup-
port of our website (http://www.igenetrain.org) as well as
other online resources for the iGeneTRAiN program; contin-
ued reporting and management of the awarded funds as they
relate to sequencing and other services related to core labs;
and the formal release of data to NIH and other sites where
appropriate. The iGeneTRAiN Statistical Group is led from
University Medical Center Utrecht, The Netherlands and is
comprised of at least 1 analyst/statistician and/or principal
investigator from each contributing iGeneTRAiN transplant
study. This group coordinates the imputation pipeline along
with association analyses pipelines, along with Pennsylvania
State University, as outlined above.
RESULTS
Tx SNPArray
To maximize power to identify novel loci associated with
transplant-related outcomes, we have designed a cost-effective
genotyping array to facilitate genomic research studies among
the Tx community. The “Tx Array” contains approximately
782,000 genetic variants, and the design was tailored to maxi-
mize precise and/or denser coverage in exonic, pharmaco-
genomic, hdCNV, LoF, MHC, and KIR, CVD/metabolic-related
loci while still maintaining strong genomewide content that is
compatible with conventional GWAS arrays. The genome-wide
coverage was designed to allow accurate imputation of unge-
notypedmarkers using sequencing-based reference panels, such
as the 1000 genomes project. We have genotyped 85 HapMap
samples (including 8 trios) and show that indeed the genotyping
quality is high with a concordance of 99.6%, and ungenotyped
SNPs can be imputed with an average accuracy of 96.2%.
A more detailed description of the Tx Array can be found
in a dedicated design article.46
Genotyping and Imputation
Of the 22 independent genotype data sets, 17 studies were
primarily genotyped using the Tx Array (n = 18338 samples
were genotyped in a single site). The remaining iGeneTRAiN
studies were genotyped across 5 genotyping sites using con-
ventional GWAS arrays (see Table 2).
Genotype imputation is the process of inferring unobserved
genotypes in a study sample based on the linkage disequilib-
rium and haplotypes observed in more densely genotyped ref-
erence samples of similar genetic background.47 Thoroughly
validated and extensively used software packages, including
IMPUTE2 andMaCH-Admix, have been used for imputation
(see Table 2) of the genomewide content using the following
population-based reference data sets: The 1000 genomes pro-
ject (1KGP), Genome of The Netherlands Consortium,48 and
UK10K49 using whole genome sequencing data from 2000 in-
dividuals (from 26 different populations), 750 (250 European
trios), and 4000 (Europeans), respectively. Comparison of
imputation accuracy and metrics from 2 independent
pipelines (both using ShapeIT/IMPUTE2 with 1000 ge-
nomes project as the reference population) show excellent
concordance.46
Because of the highly complex linkage disequilibrium and
polymorphic nature of HLA class I/II genes, we will use
SNP2HLA, a tool specifically for imputation of HLA Class
I/II.39 In addition to standard (typically biallelic) SNP impu-
tation, SNP2HLAalso infersmulti-allelic markers and amino
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acids, andmost importantly the classical HLA alleles. Testing
differences at the aggregate amino acid or HLA allele level is
more powerful than testing single SNPs, because multiple
SNP markers may have the exact same coding changes or af-
fect the same changes functionally in immune recognition.
We performed a validation of the SNP2HLA imputation
pipeline using clinical HLA typing data from European indi-
viduals within the Utrecht Heart Transplant Study, using the
HLA panel from the TxSNP array platform.46 HLA-A, -B,
-C, -DRB1, and -DQB1 were serologically typed between
1987 and 2011 in Utrecht Heart Transplant Study donors
and recipients at the University Medical Center Utrecht. We
converted the typed broad and split antigens to 2-digit using
the Nomenclature for factors of the HLA system, 2010.50
Then, we tested the concordance for each of the alleles be-
tween the 2-digit serologically typed and converted alleles
and the 2-digit alleles imputed by SNP2HLA.39 In total,
329 samples (donors and recipients combined) passed
genotyping QC and were HLA imputed. The HLA alleles
were compared in all subjects of which nonmissing data for
that allele was available, so for which 2 alleles were serolog-
ically measured. In total, between 142 (for HLA C) and
314 (for HLA DRB1) samples were included in each of
the comparisons. The imputation accuracies were 96.7%,
95.8%, 89.8%, 95.5%, and 96.1% for HLA-A, -B, -C,
DRB1, and DQB1, respectively, as shown in Table S2
(SDC, http://links.lww.com/TP/B191). With the exception
of HLA-C, which is modestly lower than the SNP2HLA
imputation accuracies within European subjects observed
in the SNP2HLA design article, the other HLA Class I/II
alleles are imputed to similar accuracies.39
Sample Size and Power
Figure 1 shows our power to detect main effect association
signals across a 5-Mb region, such as the MHC. The
statistical power calculations based on different MAFs for
the first wave of transplant phenotypes of interest: graft
survival, AR, NODAT, and DGF (in kidney only) under an
additive model in recipients, only assuming approximately
20000 tests for the MHC region. For graft failure, we have
very high power to detect a 25%minor allele frequency with
a conservatively estimated effect size of 1.2-fold increased
risk per allele. Figure 2 shows our power to detect main effect
association signals across the entire human genome assuming
a similar main effect association signals but using ~500000
SNP tests. We also have excellent power to detect modest
effect sizes across the four initial phenotypes of interest. This
indicates the overall iGeneTRAiN data set is well-powered
for common genetic variation with modest effect sizes as
can be expected in theMHC and across the genome.
DISCUSSION
Discovery of genetic factors associated with graft loss and
patient survival can generate fundamental insights into the
biological and immunological factors underpinning posttrans-
plant diseases and graft survival. Although barriers exist for
harmonizing retrospective and prospective transplant study
designs beyond single-site independent studies, international
guidelines and hard outcomes allow for standardization of
phenotypes, such as graft and patient survival, AR, NODAT,
and DGF. In addition, where feasible, participating studies
will share genotype and phenotype information between
centers to fully maximize power to detect novel biological
findings with the greater goal of conferring clinical impact.
The collapsing of phenotypes across solid-organ types may
not be ideal for organ-specific phenotypes such as kidney
DGF, for other phenotypes, in particular NODAT and
pharmacogenomic-related phenotypes, aggregation will col-
lectively improve statistical power. The current absence of
FIGURE 1. Statistical power calculations to detect main effects for the four main iGeneTRAiN phenotypes across theMajor Histocompatibility
Complex. Graft Survival in 4800 cases and 11,250 controls (top-left); AR in 3250 cases and 12,400 controls (bottom-left); NODAT in 1400
cases and 14,500 controls (top-right); DGF in 1,020 cases and 8,900 controls (kidney only) (bottom-right). The X-axes shows the OR effect
size, and the Y-axes illustrate the statistical power to detect the main effects under different MAFs: 5%, 10%, 20%, and 30% shown in blue,
red, green, and purple, respectively. Themodels are additivemodel in recipients and assume approximately 20,000 tests (Bonferroni correction
0.05). OR indicates odds ratio; MAFs, minor allele frequencies.
© 2015 Wolters Kluwer Keating et al 2407
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
adequately powered data sets makes our consortium a
unique force for GWAS efforts in Tx. The data sets in
iGeneTRAiN constitute the largest genomic and phenotypic
Txdata sets aggregated todate,with genomewide genotyping
and phenotypes collected for more than 27500 subjects
(with >11300 D-R pairs) recruited from 1993 to 2014.
The results from iGeneTRAiN will create clinical knowl-
edge and applications in a number of specific areas: (1) Knowl-
edge gained from genomewide as well asMHC/KIR variants,
whichmay be highly penetrant, will facilitate novel insight into
the biology of genomic incompatibility of D-R pairings. This
may inform better patient care through improved risk assess-
ment and monitoring of higher risk HLA D-R pairs, and/or
more tailored IST. (2) More appropriate D-R matching be-
fore Tx may be possible based onMHC/HLA and KIR geno-
type combinations, or LoF compatibility in D-R pairs (eg,
where 0 gene copies exist, ie, hdCNV, in the recipient and 1
or 2 gene copies exist in the respective donor), especially in
the living donor transplant setting where multiple potential
donors may exist. Consortia such as The Electronic Medical
Records and Genomics (eMERGE) Network have very effec-
tive models for the development of genotype/phenotype algo-
rithms from electronic medical records. The eMERGE is
currently implementing dissemination of clinical genomic tests
into electronic medical records and returning results back to
physicians and patients in a clinical care setting,51 and initial
efforts in clinically guided genotyping of tacrolimus has now
begun in one of the eMERGE/iGeneTRAiN sites.15 (3) Geno-
mic signals associatedwith clinical outcomes have been shown
to be “druggable” through repositioning of existing drugs, or
through targeting of defined small molecules known to inter-
act with genes of interest.52,53 Results from iGeneTRAiN
GWAS thus offers the potential for facilitating identification
of new therapeutics for use after Tx. (4) Genetic loci associated
with response to immunosuppressive agents (eg, calcineurin
inhibitors, mycophenolate or thymoglobulin) may also enable
personalized medicine through means, such as genotype
guided dosing of ISTs or identification of genetic variants asso-
ciated with idiosyncratic (eg, hypersensitivity) drug reactions.
The potential limitations of our study are also common to
manyGWAS efforts, including complex phenotypes with non-
genetic confounders as well as limited power to identify novel
loci and variants which may have modest effect sizes. We aim
to overcome these issues by setting up large, well-powered
studies with manually curated and harmonized phenotypes.
Nongenetic factors such as cold ischemic time and use of im-
munosuppressive drugs heavily influence clinical outcomes,
and we will use all available modelling techniques to account
for these covariates where available. However, evidence from
many phenotypes has taught us that genetic polymorphisms
with even modest independent effect sizes can uncover key
biological mechanisms in solid organ Tx outcomes.
The iGeneTRAiN aggregation of existing GWAS efforts is
essential to amass and harmonize large numbers of highly cu-
rated genotype and phenotype data sets,54 which can then
be transitioned to deep sequencing studies to gain nucleotide
resolution coverage of regions of interest. Such large initial
numbers are crucial for accrual of transplant outcome events
to inform the sequencing studies for refinement of putative
causal signals, which we believe will ultimately advance the
field.
The concept of the iGeneTRAiN network structure as a
model in Tx research is extremely powerful on a number of
fronts. First, the ability to harmonize cohorts within the same
solid-organ studies affords the ability to perform replication
look-ups of putative genetic associations in independent co-
horts, which is an absolute requirement for any large-scale
genomic study. There are minimal transplant genomic studies
FIGURE 2. Genome-wide statistical power calculations to detect main effects for the four main iGeneTRAiN phenotypes. Graft Survival in
4800 cases and 11,250 controls (top-left); AR in 3250 cases and 12,400 controls (bottom-left); NODAT in 1400 cases and 14,500 controls
(top-right); DGF in 1020 cases and 8900 controls (kidney only) (bottom-right). The X-axes shows the OR effect size, and the Y-axes illustrate
the statistical power to detect the main effects under different MAFs: 5%, 10%, 20%, and 30% shown in blue, red, green, and purple, respec-
tively. Significance is assessed at 5% level using Bonferroni correction, assuming 500,000 SNP tests
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in existence to date for such replication efforts. The ability
to discover cross-organ as well as organ-specific associa-
tions using such large sample sizes is a unique strength of
iGeneTRAiN.Wewish to encourage other studies to join this
consortium and use genome-wide genotyping arrays with
well-phenotyped samples, which can be harmonized with
the networks data sets. More appropriately phenotyped
studies will increase the statistical power through meta-
analysis to discover new loci underpinning phenotypes such
as NODAT, immunosuppression-related outcomes, DGF
and rejection. A major focus of the consortium is in-depth
analyses of HLA and KIR polymorphisms with a range of
transplant outcomes. A number of the iGeneTRAiN stud-
ies including A-WISH, CTOT-3, Deterioration of Kidney Al-
lograft Function Genomics/Gen03, genomics of chronic
renal allograft rejection have also performed functional bio-
marker studies using micro RNA, messenger RNA, proteo-
mics, and/or metabolomics as follow-up surveillance studies
to detect rejection and other complications of Tx.
In conclusion, iGeneTRAiN is a large consortium of solid-
organ transplant studies that aims to lead genomic investiga-
tions into clinical outcomes after organ Tx. Our consortium
seeks to significantly advance our understanding of the ge-
netic architecture of transplant-related outcomes and in do-
ing so, improve outcomes for these high-risk patients. The
GWAS analyses will include recipient-only analyses, D-R
mismatches with focus on LoF variants and nonsynonymous
single-nucleotide polymorphisms, and interaction analyses
between D-R pairs. Findings from this consortium are ex-
pected to provide unique insights into genomic incompatibil-
ity of D-R pairs, and fundamental incremental improvements
in knowledge of the biology underpinning rejection and com-
plications of Tx, with the ultimate goal of novel therapeutic
targets, informing personalized prescribing of immunosup-
pressive therapies, and prolonging graft and patient survival.
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